Abstract:With the development of basic research, some genetic-based methods have been found to treat Duchenne muscular dystrophy (DMD) with large deletion mutations and nonsense mutations. Appropriate therapeutic approaches for repairing multiple duplications are limited. We used the CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 system with patient-derived primary myoblasts to correct multiple duplications of the dystrophin gene. Muscle tissues from a patient carrying duplications of dystrophin were obtained, and tissue-derived primary cells were cultured. Myoblasts were purified with an immunomagnetic sorting system using CD56 microbeads. After transduction by lentivirus with a designed single guide RNA (sgRNA) targeting a duplicated region, myoblasts were allowed to differentiate for 7 days. Copy number variations in the exons of the patient’s myotubes were quantified by real-time PCR before and after genetic editing. Western blot analysis was performed to detect the full-length dystrophin protein before and after genetic editing. The ten sequences predicted to be the most likely off-targets were determined by Sanger sequencing. The patient carried duplications of exon 18–25, dystrophin protein expression was completely abrogated. Real-time PCR showed that the copy number of exon 25 in the patient’s myotubes was 2.015 ± 0.079 compared with that of the healthy controls. After editing, the copy number of exon 25 in the patient’s modified myotubes was 1.308 ± 0.083 compared with that of the healthy controls ( P < 0.001). Western blot analysis revealed no expression of the dystrophin protein in the patient’s myotubes before editing. After editing, the patient’s myotubes expressed the full-length dystrophin protein at a level that was ~6.12% of that in the healthy control samples. Off-target analysis revealed no abnormal editing at the ten sites predicted to be the most likely off-target sites. The excision of multiple duplications by the CRISPR/Cas9 system restored the expression of full-length dystrophin. This study provides proof of evidence for future genome-editing therapy in patients with DMD caused by multiple duplication mutations.

Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy

Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

Toward the correction of muscular dystrophy by gene editing

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

Long-term Maintenance of Dystrophin Expression and Resistance to Injury of Skeletal Muscle in Gene Edited DMD Mice.

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

CRISPR-Cas9 Corrects Duchenne Muscular Dystrophy Exon 44 Deletion Mutations in Mice and Human Cells.

A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing

CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

CRISPR/Cas correction of muscular dystrophies

Correction of Diverse Muscular Dystrophy Mutations in Human Engineered Heart Muscle by Single-Site Genome Editing

Mini-dCas13X–mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy

Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy

Gene-edited primary muscle stem cells rescue dysferlin-deficient muscular dystrophy

CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice

CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein

Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model